Polarean proudly welcomes Christopher von Jako, PhD, as our new Chief Executive Officer and board director! With 30 years of global healthcare leadership success, extensive experience in leading commercial-stage MedTech companies, and providing expertise across a multitude of

Are you ready to meet the experts at PVRI's Drug Discovery and Development Symposium? Taking place in Bethesda from July 10-11, the symposium brings together leading scientists, clinicians, pharma colleagues, and regulators collaborating to optimize clinical trial designs &

Polarean has received 510(k) clearance from the FDA for the Company’s specialized MRI chest coil to now include its use with Philips 3.0T MRI scanners for the visualization of the Xenon-129 (129Xe) nuclei. This milestone further supports the recently announced collaboration with

Polarean would like to show support as we begin Pulmonary Fibrosis Awareness Month. More than 250,000 Americans live with pulmonary fibrosis and interstitial lung disease, and there is no known cure. Polarean remains passionate about developing imaging technologies that can aid

Polarean was pleased to support and lead several discussions at the Annual Xenon MRI Clinical Trial Consortium Meeting last week. This 3-day gathering of prominent academic scientists, expert clinicians, and industry representatives continues to highlight the current state of the

Polarean's chief scientific officer, Professor Bastiaan Driehuys, presented the latest science on #XenonMRI at the annual congress of Pulmonary Vascular Research Institute (PVRI) in London today.  He initially discussed the latest findings on behalf of his colleagues at Duke

Graft-versus-host disease, or #GVHD, is a medical condition that can occur after a bone marrow or stem cell transplant. In this condition, the donor cells (graft) attack the organs and tissues of the person receiving the transplant (host). There are two types of GVHD: acute

Congratulations to our collaborators Rachel Eddy, David Mummy, Peter Niedbalski, et al. on their recent original research publication entitled, “Cluster Analysis to Identify Long COVID Phenotypes Using 129Xe Magnetic Resonance Imaging: A Multi-centre Evaluation.” These

We're thrilled to be attending as a featured poster company at yet another Respiratory Innovation Summit! These gatherings consistently spark enriching discussions that drive #innovation in respiratory research. Following #RIS2024, the 2024 ATS International Conference will

A new study at Duke Health leveraged #XenonMRI to compare bilateral lung transplant patients with known chronic lung allograft dysfunction (CLAD) to healthy volunteers. Sensitive and noninvasive methods of screening for CLAD are essential, given the 60% five-year survival rate

We are pleased to announce the appointment of Dr. Chase Hall, M.D. as our Chief Medical Advisor. Dr. Hall is an Associate Professor of Pulmonary, Critical Care, and Sleep Medicine at the University of Kansas Medical Center and Associate Director at the KU Medical Center Interstitial

Congratulations to Prof. David Mummy of Duke University for his outstanding presentation on #XenonMRI at the 11th International Workshop on Pulmonary Functional Imaging in Japan last week. His poster at the event, "Estimating Physiological Values of Membrane and RBC Conductance Using

We welcome Alan Huang, PhD, as our new Vice President of Sales. Previously at Philips, Dr. Huang brings extensive knowledge and 15 years of experience in the medical device industry, with specific expertise in MRI and MRI-based technologies. At Polarean, he will be responsible

During Pulmonary Fibrosis Awareness Month (#PFAM), one of the best ways to increase awareness is to join together with those who have been impacted by this disease. Throughout September, check out the Pulmonary Fibrosis Foundation site to share your story and learn how members of this community are

We are thrilled to see more advancements in lung imaging biomarkers! Researchers like Prof. Rachel Eddy, her team at the University of British Columbia and Chase Hall are harnessing the combined power of CT and MRI imaging biomarkers to generate new insights into lung health

During Pulmonary Fibrosis Awareness Month (#PFAM), visit Pulmonary Fibrosis Foundation to learn about this disease and how it impacts patients and family members. Today's story on PFF social media is from our CEO, Dr. Christopher von Jako, who lost his physician father in 2015 to IPF. "I joined

Tomorrow is #WorldLungDay! Did you know that respiratory diseases are leading causes of death and disability in the world? #Asthma impacts more than 350 million people worldwide, making it the most prevalent chronic disease in children. Each year, #pneumonia claims more than 2.4

Virtual Investor Day: Oct. 9 Join us for our Virtual Investor Day on Wednesday, October 9 at 9:00am EDT / 2:00pm BST. The Zoom webinar will showcase our innovative #XenonMRI functional lung imaging platform, its clinical use and future utility, as well as our commercial